Interstitial Lung Diseases (ILDs) encompass a diverse group of over 200 conditions characterized by inflammation and fibrosis of the lung parenchyma. They pose significant diagnostic and therapeutic challenges, often leading to progressive pulmonary fibrosis and respiratory failure.
ILDs are primarily driven by an aberrant wound healing response to various triggers, leading to alveolar epithelial injury, inflammation, and fibroblast proliferation. This results in the replacement of normal lung architecture with fibrotic tissue, impairing gas exchange and leading to restrictive lung disease.
ILDs can be idiopathic or associated with systemic diseases. Idiopathic Pulmonary Fibrosis (IPF) is the most common idiopathic ILD, while Connective Tissue Disease-associated ILDs (CTD-ILDs) are common secondary ILDs. Other forms include Hypersensitivity Pneumonitis, Occupational ILDs, and Sarcoidosis.
Patients typically present with progressive dyspnea and non-productive cough. Diagnosis involves a combination of clinical history, radiological findings, and often, histological confirmation. High-resolution computed tomography (HRCT) is critical for identifying typical radiographic patterns.
Management of ILDs is complex and often requires a multidisciplinary approach. The mainstay of treatment is immunosuppression, with the addition of antifibrotic agents in certain cases. Lung transplantation may be considered in advanced disease. Importantly, comorbidity management and palliative care play a significant role in patient outcomes.
ILDs represent a complex group of diseases with a significant impact on patient morbidity and mortality. Early recognition, accurate diagnosis, and appropriate management are crucial in altering the disease course. As healthcare professionals, staying abreast of the latest advancements in ILD research is imperative to provide optimal patient care.
1.
A US health panel advises starting mammograms at age 40 rather than 50.
2.
TULSA Is Effective in Long-Term Prostate Cancer Control.
3.
J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79
4.
In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".
5.
How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma
1.
Molecular Matching for Individualized Blood-Disorder Therapy
2.
Everything You Need To Know About Melanoma Choroid: Causes, Symptoms, and Treatment
3.
Drug Safety Surveillance of Long-Term Medication Effects in Cancer Survivorship
4.
HPV-Related Cervical Cancer: Advances in Screening, Preventiofn & Treatment
5.
Early Diagnosis of Lung Cancer Through Emerging Biomarkers
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Current Scenario of Cancer- The Incidence of Cancer in Men
2.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
3.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
4.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation